TLC - Taiwan Liposome Company, Ltd.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
5.20
0.00 (0.00%)
At close: 9:30AM EDT
Stock chart is not supported by your current browser
Previous Close5.20
Open5.25
Bid5.00 x 900
Ask5.23 x 1400
Day's Range5.20 - 5.20
52 Week Range4.88 - 11.00
Volume30
Avg. Volume906
Market Cap172.116M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.51
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est13.00
Trade prices are not sourced from all markets
  • GlobeNewswire

    TLC Reports Third Quarter 2019 Financial Results and Provides Business Update

    SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Oct. 22, 2019 -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines.

  • GlobeNewswire

    TLC Presents Clinical and Preclinical Data of TLC590 at ANESTHESIOLOGY® Annual Meeting and in International Journal of Nanomedicine

    TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need in pain management, ophthalmology and oncology, recently presented data at the American Society of Anesthesiologists (ASA) ANESTHESIOLOGY® annual meeting from a Phase I/II clinical trial which showed TLC590 to yield more immediate and long-lasting pain reduction than ropivacaine. In addition, in vivo findings in which TLC590 showed no dose-related toxicity and other preclinical data were recently published in the International Journal of Nanomedicine.

  • GlobeNewswire

    TLC Appoints Vincent Chang, PhD, as Vice President of Manufacturing Development

    TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company dedicated to the development and commercialization of novel nanomedicines designed to target areas of unmet medical need in pain management, ophthalmology and oncology, today announced the appointment of Vincent Chang, PhD, as TLC’s Vice President of Manufacturing Development. With over 35 years of experience attained at Abbott, Roche, GlaxoSmithKline and Bayer, Dr. Chang will serve as a member of the TLC Management Team and guide the company in affairs related to the chemistry, manufacturing and controls of its products.

  • GlobeNewswire

    TLC to Present Potential Cartilage-Protecting Effects of TLC599 on the Knee at 2019 ACR Annual Meeting

    TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company dedicated to the development and commercialization of novel nanomedicines designed to target areas of unmet medical need in pain management, ophthalmology and oncology, will be presenting magnetic resonance imaging (MRI) results of the potential protective effects of TLC599 on knee cartilage at the American College of Rheumatology 2019 ACR/ARP Annual Meeting in Atlanta, Georgia. TLC599 is a BioSeizer® sustained release formulation of dexamethasone sodium phosphate (DSP) which demonstrated durable pain relief and improved function over 24 weeks in patients with knee osteoarthritis pain in a Phase II clinical trial.

  • GlobeNewswire

    TLC Announces Initiation of Phase III Pivotal Clinical Trial of TLC599 for the Treatment of Osteoarthritis Knee Pain

    TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company dedicated to the development and commercialization of novel nanomedicines designed to target areas of unmet medical need in pain management, ophthalmology and oncology, today announced the initiation of a Phase III clinical trial (“EXCELLENCE”) to evaluate the efficacy and safety of single as well as repeated doses of TLC599 in patients with osteoarthritis (OA) of the knee. TLC599 is a BioSeizer® sustained release formulation of dexamethasone sodium phosphate (DSP) intended for the management of OA pain.

  • GlobeNewswire

    TLC to Present Preclinical Data on TLC178 at ESMO 2019

    SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Sept. 23, 2019 -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company dedicated to the development.

  • GlobeNewswire

    TLC to Present as Panelist among Key Opinion Leaders at the BTIG Pain Management Forum

    SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Sept. 03, 2019 -- TLC (Nasdaq: TLC, TWO: 4152) announced today that the Company’s management team has been invited to.

  • GlobeNewswire

    TLC to Present at Upcoming Investor Conferences in September 2019

    SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Aug. 28, 2019 -- TLC (Nasdaq: TLC, TWO: 4152) today announced that the management team is scheduled to present at the two.

  • GlobeNewswire

    TLC Reports Second Quarter 2019 Financial Results and Provides Business Update

    SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, July 30, 2019 -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company dedicated to the development.

  • GlobeNewswire

    TLC Announces Development and License Agreement with Birdie Biopharmaceuticals for NanoX™ Immunotherapy Product

    SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, June 25, 2019 (GLOBE NEWSWIRE) -- Taiwan Liposome Company, Ltd. (“TLC”) (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company dedicated to the development and commercialization of novel nanomedicines designed to target areas of unmet medical need in osteoarthritis, pain management, ophthalmology and oncology, today announced the signing of a development and license agreement with Birdie Biopharmaceuticals Inc. (“Birdie”), a wholly owned subsidiary of Seven and Eight Biopharmaceuticals Corp. Birdie and Seven and Eight Biopharmaceuticals are clinical stage biotech companies focused on the development of immunotherapy to treat cancer.

  • GlobeNewswire

    TLC Announces Part 1 Analysis of TLC590 Phase II Clinical Trial for Postsurgical Pain Management following Bunionectomy

    TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company dedicated to the development and commercialization of novel nanomedicines designed to target areas of unmet medical need in osteoarthritis, pain management, ophthalmology and oncology, today announced results from the pre-planned analysis of Part 1 of TLC590’s Phase II clinical trial in patients following bunionectomy. TLC590 is a proprietary BioSeizer® liposomal formulation of ropivacaine intended for the relief of postsurgical pain.

  • GlobeNewswire

    TLC Presents New Pharmacokinetic and Toxicokinetic Data on TLC599 Following Intra-articular Injection in Dogs at EULAR 2019

    SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, June 12, 2019 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company dedicated to the development and commercialization of novel nanomedicines designed to target areas of unmet medical need in osteoarthritis, pain management, ophthalmology and oncology, today announced that new pharmacokinetic and toxicokinetic data are presented on TLC599 following intra-articular injections in dogs at the Annual European Congress of Rheumatology (EULAR 2019) on Thursday, June 13th in Madrid, Spain. Results from the study showed that TLC599, a proprietary BioSeizer® sustained release formulation of dexamethasone sodium phosphate, has the potential to be a long-lasting chronic treatment for osteoarthritis pain.

  • GlobeNewswire

    TLC Reports First Quarter of 2019 Financial Results and Provides Business Update

    SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, May 08, 2019 -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company dedicated to the.

  • GlobeNewswire

    TLC Highlights Data Presentations on Lead Product Candidate TLC599 at Osteoarthritis Research Society International (OARSI) 2019 World Congress

    SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, May 06, 2019 -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company dedicated to the development and.

  • GlobeNewswire

    TLC Earns Highest Ranks in Corporate Governance Evaluation for 5th Consecutive Year

    SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, May 02, 2019 -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company dedicated to the development and.

  • GlobeNewswire

    TLC to Present at Upcoming Conferences

    SOUTH SAN FRANCISCO, CA and TAIPEI, Taiwan, April 22, 2019 -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company dedicated to the development and.

  • GlobeNewswire

    TLC Announces Positive End-of-Phase II Meeting with FDA for TLC599 in Knee Osteoarthritis

    TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company dedicated to the development and commercialization of novel nanomedicines designed to target areas of unmet medical need in osteoarthritis, pain management, ophthalmology and oncology, today announced the successful completion of its End-of-Phase II meeting with the U.S. Food and Drug Administration (FDA) on receiving guidance, and discussing the clinical and regulatory pathway for a potential U.S. approval of TLC599, a BioSeizer® liposomal formulation of dexamethasone sodium phosphate for the treatment of knee osteoarthritis. In agreement with the FDA, the Company believes its proposed overall design of a single global pivotal Phase III trial will be sufficient to support a New Drug Application (NDA) submission.

  • GlobeNewswire

    TLC Announces Full Enrollment in Part 1 of Phase II Trial of TLC590 for Postsurgical Pain Management following Bunionectomy

    TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company dedicated to the development and commercialization of novel nanomedicines designed to target areas of unmet medical need in osteoarthritis, pain management, ophthalmology and oncology, today announced the earlier-than-scheduled full enrollment in Part 1 of TLC590’s Phase II clinical trial in patients following bunionectomy. TLC590 is a proprietary BioSeizer® liposomal formulation of ropivacaine engineered to provide fast and sustained postsurgical pain relief for up to 96 hours. Results from Part 1 of the Phase II clinical trial are expected in mid-2019.

  • GlobeNewswire

    TLC Reports Fourth Quarter and Full Year 2018 Financial Results and Business Update

    SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, April 01, 2019 -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company dedicated to the development.

  • GlobeNewswire

    TLC to Present High-Scoring Scientific Abstracts on Acute Pain through Moderated Sessions at ASRA Spring 2019

    SOUTH SAN FRANCISCO, Calif. and TAIPAI, Taiwan, March 25, 2019 -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company dedicated to the development.

  • GlobeNewswire

    TLC Announces First Patient Dosed in Phase II Trial of TLC590 for Postsurgical Pain Management following Bunionectomy

    TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company dedicated to the development and commercialization of novel nanomedicines designed to target areas of unmet medical need in osteoarthritis, pain management, ophthalmology and oncology, today announced that the first patient has been dosed a Phase II clinical trial for TLC590 following bunionectomy. TLC590 is a proprietary BioSeizer™ liposomal formulation of ropivacaine engineered to provide fast and sustained postsurgical pain relief for up to 96 hours, as recently demonstrated in a Phase I/II clinical trial. The Phase II, randomized, double-blind, comparator- and placebo-controlled clinical trial will evaluate the safety, pharmacokinetics, and efficacy of TLC590 compared with ropivacaine and placebo via a single infiltrative local administration in approximately 200 patients following bunionectomy across five sites in the US.

  • GlobeNewswire

    TLC Reports Positive Top-Line Results from Phase I/II Clinical Trial of TLC590 for Postsurgical Pain

    TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company dedicated to the development and commercialization of novel nanomedicines designed to target areas of unmet medical need in osteoarthritis, pain management, ophthalmology and oncology, today reported positive top-line results from the first in human Phase I/II clinical trial of TLC590, a proprietary BioSeizer™ sustained release formulation of ropivacaine, for postsurgical pain management. This randomized, double-blind, active-controlled, dose-escalation study evaluated the safety and tolerability of a single administration of TLC590 at four doses (190mg, 380mg, 475mg and 570mg) compared to a standard dose of ropivacaine (150mg, dose strength equivalent to 90mg bupivacaine) in 64 adult patients following inguinal hernia repair surgery.

  • GlobeNewswire

    TLC and 3SBio Form Exclusive Partnership to Commercialize Two NanoX™ Products in Mainland China

    Taiwan Liposome Company, Ltd. (“TLC”)(Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company dedicated to the development and commercialization of novel nanomedicines designed to target areas of unmet medical need in osteoarthritis, pain management, ophthalmology and oncology, and 3SBio Inc. ("3SBio")(1530.HK), a leading Chinese biopharmaceutical company specializing in oncology, nephrology, auto immune diseases, metabolic disorders and dermatology, today announced an exclusive partnership to commercialize in mainland China two liposomal products utilizing TLC’s proprietary NanoX™ technology platform. Under this alliance, TLC and 3SBio will cooperate to obtain regulatory approvals in mainland China, TLC will utilize its commercial-scale manufacturing capabilities to supply the two liposome products for 3SBio to commercialize in mainland China.

  • GlobeNewswire

    TLC Appoints George Spencer-Green, MD, MS, as Chief Medical Officer

    Taiwan Liposome Company, Ltd. (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company dedicated to the development and commercialization of novel nanomedicines designed to target areas of unmet medical need in osteoarthritis, pain management, ophthalmology and oncology, today announced the appointment of George Spencer-Green, MD, MS, as TLC’s new Chief Medical Officer. With more than three decades of clinical medicine and drug development experience, Dr. Spencer-Green will serve as a member of the TLC Management Team and guide the company in its clinical and regulatory activities.

  • GlobeNewswire

    EMA Grants Orphan Drug Designation to TLC178 for the Treatment of Soft Tissue Sarcoma

    Taiwan Liposome Company, Ltd. (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company dedicated to the development and commercialization of novel nanomedicines designed to target areas of unmet medical need in pain management, ophthalmology and oncology, today announced that the European Medicines Agency (EMA) has granted orphan drug designation for TLC178 for the treatment of soft tissue sarcoma. Soft tissue sarcomas are cancers of the body's connective or supportive tissues, such as cartilage, fat, muscle, fibrous tissue, and blood vessels.